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Purpose: With the increasing number of retinal gene-based therapies and therapeutic constructs, in vitro bioassays
characterizing vector transduction efficiency and quality are becoming increasingly important. Currently, in vitro assays
quantifying vector transduction efficiency are performed predominantly for non-ocular tissues. A human retinal pigment
epithelial cell line (ARPE19) and a mouse cone photoreceptor cell line, 661W, have been well characterized and are used
for many retinal metabolism and biologic pathway studies. The purpose of this study is to quantify transduction efficiencies
of a variety of self-complementary (sc) adeno-associated virus (AAV) vectors in these biologically relevant ocular cell
lines using high-throughput fluorescence-activated cell sorting (FACS) analysis.
Methods: ARPE19 and 661W cells were infected with sc-smCBA-mCherry packaged in unmodified AAV capsids or
capsids containing single/multiple tyrosine-phenylalanine (Y-F) mutations at multiplicity of infections (MOIs) ranging
from 100 to 10,000. Three days post infection fluorescent images verified mCherry expression. Following microscopy,
FACS analysis was performed to quantify the number of positive cells and the mean intensity of mCherry fluorescence,
the product of which is reported as transduction efficiency for each vector. The scAAV vectors containing cone-specific
(sc-mCARpro-green fluorescent protein [GFP]), rod-specific (sc-MOPS500-eGFP), retinal pigment epithelium (RPE)-
specific (sc-VMD2-GFP), or ubiquitous (sc-smCBA-GFP) promoters were used to infect both cell lines at an MOI of
10,000. Three days post infection, cells were immunostained with an antibody raised against GFP and imaged. Finally,
based on our in vitro results, we tested a prediction of transduction efficiency in vivo.
Results: Expression from unmodified scAAV1, scAAV2, scAAV5, and scAAV8 vectors was detectable by FACS in both
ARPE19 and 661W cells, with scAAV1 and scAAV2 being the most efficient in both cell lines. scAAV5 showed moderate
efficiency in both ARPE19 and 661W cells. scAAV8 was moderately efficient in 661W cells and was by comparison less
so in ARPE19 cells; however, transduction was still apparent. scAAV9 performed poorly in both cell types. With some
exceptions, the Y-F capsid mutations generally increased the efficiency of scAAV vector transduction, with the increasing
number of mutated residues improving efficiency. Results for single scAAV1 and scAAV8 capsid mutants were mixed.
In some cases, efficiency improved; in others, it was unchanged or marginally reduced. Retinal-specific promoters were
also active in both cell lines, with the 661W cells showing a pattern consistent with the in vivo activity of the respective
promoters tested. The prediction based on in vitro data that AAV2 sextuple Y-F mutants would show higher transduction
efficiency in RPE relative to AAV2 triple Y-F capsid mutants was validated by evaluating the transduction characteristics
of the two mutant vectors in mouse retina.
Conclusions: Our results suggest that this rapid and quantifiable cell-based assay using two biologically relevant ocular
cell lines will prove useful in screening and optimizing AAV vectors for application in retina-targeted gene therapies.
Advances  in  the  development  of  recombinant  adeno-
associated virus (AAV) vectors together with recent successes
in using AAVs in human clinical trials of retinal disease have
resulted in an explosion in the use of AAVs for retina-targeted
gene therapy. With the increase in number of characterized
serotypes (both naturally occurring and engineered) and the
availability of tissue-specific promoters, more emphasis has
been placed on targeting specific cell types within the retina
or  even  subclasses  of  cell  types  (e.g.,  cones  versus  all
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photoreceptors). Results of several ongoing phase I/II clinical
trials  for  RPE65-Leber  congenital  amaurosis-2  (LCA2)
indicate that AAV-mediated Rpe65 delivery to the retinal
pigment epithelium (RPE) is both safe and effective [1-4].
Several successful proof-of-concept studies involving mice,
dogs, and monkeys have established that AAV-mediated gene
replacement  is  also  a  feasible  strategy  for  treating
photoreceptor-specific  disorders  [5-8].  More  specifically,
because of their contribution to acute, daylight vision, much
attention  has  been  paid  to  disorders  affecting  cone
photoreceptors.  As  with  LCA2,  the  successful  clinical
application of vectors to treat these diseases will depend on
the  ability  to  express  sufficient  levels  of  AAV-mediated
therapeutic protein in these cell types.
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1090The  ability  to  quickly  characterize  the  transduction
profiles of novel AAV vectors in biologically relevant, ocular
cell lines would aid in developing vectors to treat retinal
disease. There would be much to gain by having the ability to
predict in vivo transduction efficiencies of the various capsid
serotypes and capsid mutants through the use of a fast, high-
throughput, in vitro assay. Such an assay would be valuable
both  at  the  ‘front  end’  of  gene  therapy  trials  to  quickly
determine which serotype and/or promoter would potentially
provide  the  level  of  transduction  efficiency  required  for
therapy at the proof-of-concept stage and at the ‘back end’ to
develop  appropriate  cell-based  assays  to  qualify  clinical-
grade  vectors  as  part  of  a  regulatory  review  before  drug
approval  and  future  vector  stability  testing.  The
aforementioned  retinal  disorders  highlight  how  cells  that
retain characteristics of RPE or cone photoreceptors would be
particularly useful in such an assay.
The human retinal pigment epithelial cell line (ARPE19)
is a spontaneously evolved, diploid human cell line, purified
by selective trypsinizations of a primary RPE culture [9]. The
cells  have  a  normal  karyotype,  form  polarized  epithelial
monolayers when cultured, and express several RPE-specific
proteins [9]. They have been widely used as a model system
for RPE, including studies evaluating key signaling pathways
and responses to light damage and reactive oxygen species
(ROS) [10-13]. The permeability characteristics of polarized
ARPE19 monolayers improve with prolonged culturing and
they  are  currently  being  used  as  a  pharmacological  and
physiologic model to evaluate the barrier function of the outer
retinal blood barrier [14,15]. A cell line of neural retina origin,
661W  cone  cells,  was  immortalized  by  the  expression  of
SV40-T  antigen  under  control  of  the  human
interphotoreceptor retinoid-binding protein (IRBP) promoter
[16]. The 661W cells express cone but not rod photoreceptor
markers, including red/green opsin and cone cyclic nucleotide
gated channel subunits. They respond to light stimulation and
undergo cell death when stressed by bright light [16,17]. They
are increasingly being used as a surrogate to evaluate cone cell
survival in response to oxidative stress/ROS in vitro [10,18].
In addition to the above characteristics, both cell lines are
relatively easy to acquire and maintain. The purpose of this
study was to use these biologically relevant ocular cell lines,
ARPE19 and 661W (RPE and cone photoreceptor surrogates,
respectively), to develop a high-throughput assay to quantify
the transduction efficiencies of a variety of AAV vectors. We
focused specifically on the relative transduction efficiencies
of self-complementary vectors with capsids that were either
unmodified or that contained single/multiple point mutations
in which surface-exposed tyrosine residues were changed to
phenylalanine  (Y-F).  We  have  shown  that  AAV  vectors
containing  Y-F  capsid  mutations  exhibit  increased
transduction efficiency in the retina relative to those with
unmodified capsids [19]. Additionally, we have shown that an
AAV capsid mutant vector was capable of restoring long-term
retinal function and visual behavior and preventing retinal
degeneration  in  an  animal  model  of  recessive  retinitis
pigmentosa, the rd10 mouse model. This model is refractory
to treatment with unmodified AAV vectors [20]. Here, we
report  the  transduction  efficiencies  of  each  vector  and
examine the activity of several cell-specific and ubiquitous
promoters with well characterized activity in ARPE19 and
661W  cells,  two  biologically  relevant  ocular  cell  lines.
Additionally,  by  comparing  the  results  of  transduction
efficiencies for a subset of AAV2 Y-F mutants in mouse retina
(i.e., in vivo) to our in vitro results, we evaluated the predictive
utility of the assay.
METHODS
Construction  of  AAV  vectors:  Self-complimentary  rAAV
serotypes 1, 2, 5, 8, 9, and their corresponding single and
multiple  tyrosine-to-phenylalanine  (Y-F)  mutants,  all
containing the ubiquitous, truncated chimeric Cmv-chicken
β-actin (smCBA) promoter [21] driving the mCherry reporter
cDNA, were generated and purified by previously described
methods [22,23]. Vectors were titered by quantitative real-
time PCR and re-suspended in re-suspended in balanced salt
solution (BSS; Alcon, Fort Worth, TX) [24].
Cell  culture:  The  ARPE19  (purchased  from  ATCC)  and
661W cone cells (generously provided by Dr. Muayyad R. Al-
Ubaidi,  University  of  Oklahoma  Health  Sciences  Center,
Oklahoma City, OK) were routinely passaged by dissociation
in 0.05% (w/v) trypsin and 0.02% (w/v) EDTA, followed by
replating at a split ratio ranging from 1:3 to 1:5 in T75 flasks.
Cells used for experiments were between passages 15 and 30.
Cell morphology and growth rates were closely monitored at
all steps to ensure cell line identity. The ARPE19 cells were
maintained  in  culture  medium  consisting  of  Dulbecco’s
modified Eagle’s medium (DMEM): Nutrient Mixture F12,
1:1 mixture with Hepes buffer containing 10% fetal bovine
serum (FBS), 0.348% (w/v) additional sodium bicarbonate,
1% 200 mM L-glutamine, and 50 mg/ml Gentamicin [9]. The
661W cone cells were maintained in DMEM containing 10%
FBS, 300 mg/l glutamine, 32 mg/l putrescine, 40 µl of β-
mercaptoethanol,  and  40  µg  of  hydrocortisone  21-
hemisuccinate and progesterone. The media also contained
penicillin (90 units/ml) and streptomycin (0.09 mg/ml) [16].
Cultures were incubated at 37 °C in 7% CO2.
Infections: Cells were plated in 96-well plates and achieved
60%–70%  confluency  after  overnight  incubation.  This
confluency was achieved with seeding counts of 1.0×104 -
3.0×104  cells/well.  Twenty-four  hours  post  seeding,
confluency was confirmed by bright-field microscopy (Nikon
Diaphot). Next, AAV vectors were diluted in BSS and serum-
free media to achieve the desired multiplicity of infection
(MOI). MOI was defined as the number of genome containing
vector  particles  per  target  cell.  Since  recombinant  AAV
vectors have much lower physical to infectious particle ratios
than  1:1,  typically  1:20  to  1:100  [25],  MOI  in  our  case
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particles  per  target  cell.  Cells  were  rinsed  in  phosphate
buffered saline (PBS) and the virus dilutions were applied at
MOIs ranging from 100 to 10,000. After 1 h, 20% serum-
containing media was added to the cells. Infected cells were
incubated  at  37  °C  in  7%  CO2  for  3  days,  except  where
otherwise  indicated.  All  infections  were  performed  in
triplicate. Each vector was used to infect 24 wells in total.
Each “sample” was pooled from eight wells, making a final
sample count of three. For long-term ARPE19 infection, cells
were infected with scAAV2-smCBA-mCherry at an MOI of
10,000, as described above, and incubated for 14 days at 37 °C
in 7.0% CO2. The 10% F-12 media was exchanged twice a
week. Fluorescent images were taken at 3, 7, and 14 days post
infection.
Microscopy and fluorescence activated cell sorting analysis:
Three days post infection, cells were observed using bright-
field microscopy to ensure 100% confluency. Cells were then
analyzed  using  fluorescent  microscopy  (Olympus  IX70
Inverted Fluorescent Microscope equipped with a QImaging
Retiga  4000R  Camera  with  RGB-HM-5  Color  Filter  and
QImaging QCapture Pro 6.0 software; QImaging Surrey, BC
Canada). All images were taken at identical exposure settings
(800 ms) and magnification (10×). mCherry expression was
detected with a Semrock Bright Line TRITC-A filter with an
excitation wavelength of 543 nm and an emission band pass
of 553–633 nm. Finally, cells were dissociated with Accutase
solution (MP Biomedicals, Solon, OH) and 10,000 cells per
sample were counted and analyzed using a BD LSR II flow
cytometer equipped with BD FACSDIVA 6.2 software (BD
Biosciences, San Jose, CA). Uninfected control cells were
also counted and analyzed to establish transduction efficiency
baselines. Data was obtained from three samples for each
vector.  mCherry  fluorescence  was  quantified  with  a  PE-
Texas-Red-A filter with an excitation wavelength of 532 nm
and an emission band pass of 600–620 nm. The transduction
efficiency of each AAV serotype and their respective Y-F
capsid  mutants  were  then  calculated  by  multiplying  the
percentage  of  cells  positive  for  mCherry  by  the  mean
fluorescence intensity [26]. The values of three samples for
each vector were then averaged to obtain a final transduction
efficiency value for each serotype.
Promoter  analysis:  Serotype  2  self-complementary  AAV
vectors, containing the ‘humanized’ green fluorescent protein
(GFP)  reporter  cDNA  and  one  of  four  tissue-specific  or
ubiquitous promoters, were packaged and purified according
to  methods  previously  described  [22-24].  Photoreceptor-
specific promoters included the 501 bp mouse cone arrestin-3
(mCARpro) promoter [27] and the 471 bp mouse rod opsin
(MOPS500) promoter [28]. The RPE-specific and ubiquitous
promoters chosen were a 624 bp version of the vitelliform
macular dystrophy/Best disease (VMD2) promoter [29] and
smCBA [21], respectively. The ARPE19 and 661W cells were
separately seeded in 24-well plates, achieving cell counts of
1.0×105 cells/well. Twenty-four hours post seeding, the cells
were exposed to each vector at an MOI of 10,000. Infections
were performed as previously described in Method section.
At  3  days  post  infection,  immunostaining  was  performed
according  to  previously  described  methods,  with  minor
modifications  [5].  Briefly,  cells  were  fixed  in  4%
paraformaldehyde for 5 min, followed by three washes in 1×
PBS  (HyClone  Laboratories,  Inc.  Logan,  UT),  a  15  min
incubation in 0.5% Triton X-100 (diluted in 1× PBS), and a
30 min incubation in 1% bovine serum albumin (diluted in 1×
PBS), all at room temperature. Cells were then incubated in
primary  antibody  directed  against  GFP  (A11122;  rabbit
polyclonal,  Invitrogen)  diluted  1:400  in  0.3%  Triton
X-100/1%  BSA  at  room  temperature  for  3  h.  Following
primary incubation, cells were washed three times with PBS
and incubated with secondary antibody (goat-anti rabbit IgG
tagged with Alexa-Fluor 488, A11008; Invitrogen) diluted
1:500 in PBS for 1 h at room temperature. Lastly, cells were
counterstained with 4’, 6’-diamino-2-phenylindole for 5 min
at room temperature. Images were taken with the fluorescent
scope, as previously described in the Methods section. A
Semrock  Bright  Line  GFP-3035B  filter  (Semrock,  Inc.,
Rochester, NY) with an excitation wavelength of 472 nm and
an emission band pass of 485 nm–555 nm was used to detect
GFP expression. Images of cells infected with mCARpro-,
MOPS500-,  and  VMD2-containing  vectors  were  taken  at
identical exposure settings (800 ms) and magnification (10×),
while 10× images of cells infected with smCBA-containing
vectors were taken at an exposure time of 300 ms.
In  vivo  analysis:  All  animals  used  in  the  study  were
maintained at the University of Florida Health Science Center
in  the  animal  care  facilities  under  a  12  h:12  h  light-dark
environment  and  were  handled  in  accordance  with  the
Association  for  Research  in  Vision  and  Ophthalmology
(ARVO) statement for the Use of Animals in Ophthalmic and
Vision Research and the guidelines of the Institutional Animal
Care and Use Committee at the University of Florida. Adult
C57BL/6 mice were anesthetized with a mixture of ketamine
(72 mg/kg)/xylazine (4 mg/kg) by intraperitoneal injection
and were subretinally injected with 1 µl of vector at a titer of
1×1013 genome copies per ml, as previously described [30].
The  AAV2-CBA-GFP  triple  mutant  (Y444F+Y730F
+Y500F)  and  AAV2-CBA-GFP  sextuple  mutant  (Y444F
+Y730F+Y500F+Y272F+Y704F+Y252F)  used  for  this
portion of the study have been previously described [31].
RESULTS
Transduction  efficiency  of  unmodified,  self-complimentary
AAV  vectors  in  ARPE19  and  661W  cells:  The  scAAV
serotypes 1, 2, 5, 8, and 9 infected in both ARPE19 and 661W
cells  at  MOIs  ranging  from  100  to  10,000  and  their
transduction  efficiencies  (as  measured  by  mCherry
expression) were analyzed three days later by flow cytometry.
Here, we present data generated from cells infected only at an
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across all MOIs. Our results indicate scAAV1 and scAAV2
had  the  highest  transduction  efficiency  in  both  cell  lines
(Figure 1). In ARPE19 cells, scAAV1 and scAAV2 had very
similar transduction efficiencies. scAAV5 and scAAV8 had
substantially lower transduction efficiencies than scAAV1
and scAAV2 (10-fold and 100 fold lower, respectively). In
661W  cells,  scAAV1  had  2.5  fold  higher  transduction
efficiency than scAAV2. scAAV5 and scAAV8 had similar
transduction efficiencies, both sevenfold lower than scAAV2.
scAAV9 had the lowest transduction efficiency in both cell
lines.
Transduction  efficiency  of  modified  scAAV2  vectors  in
ARPE19 and 661W cells: We have shown that serotype 2
AAV vectors containing multiple combinations of Y-F capsid
mutations exhibit increased transduction efficiency relative to
unmodified AAV2 vectors in adult mouse retinas [19]. Here,
we evaluate whether the same pattern can be found in the
ARPE19 and 661W ocular cell lines. Vectors tested included
the scAAV2 single mutant (Y444F), double mutant (Y444F
+Y730F), triple mutant (Y444F+Y730F+Y500F), quadruple
mutant  (Y444F+Y730F+Y500F+Y272F),  pentuple  mutant
(Y444F+Y730F+Y500F+Y272F+Y704F),  and  sextuple
mutant  (Y444F+Y730F+Y500F+Y272F+Y704F+Y252F).
Infections were performed as previously described. We found
that all scAAV2 Y-F capsid mutants have higher transduction
efficiencies than unmodified scAAV2 (Figure 2). Of all the
vectors,  the  scAAV2  sextuple  mutant  had  the  highest
transduction  efficiency  in  both  cell  lines;  its  transduction
efficiency was 12.5 fold and 9 fold higher than unmodified
scAAV2 in ARPE19 and 661W cells, respectively.
In  vivo  confirmation  of  in  vitro  transduction  patterns  for
selected AAV2 Y-F mutants: In Figure 2, the scAAV2 sextuple
Y-F mutant was shown to be the most efficient multiple Y-F
mutant in ARPE19 cells, approximately threefold higher than
the triple Y-F mutant, whereas in 661W cells the triple and
sextuple Y-F mutants were equally efficient. Based on this
observation,  we  would  predict  that,  in  vivo,  the  sextuple
mutant  would  show  significantly  higher  transduction
efficiency in RPE that the triple mutant. Figure 3 demonstrates
that,  when  delivered  to  the  subretinal  space,  the  AAV2
sextuple mutant mediates more efficient transduction of RPE
than a matched (same construct and vector titer) AAV2 triple
mutant and that when compared, the relative efficiencies of
these vectors in vitro and in vivo (Figure 2 and Figure 3,
respectively) are well correlated.
Fluorescent  microscopy  analysis:  In  addition  to  FACS
analysis, fluorescent images were taken of all infections at all
MOIs at 3 days post infection. Representative images shown
in Figure 4 are of ARPE19 or 661W cells infected at an MOI
of  10,000.  Because  scAAV1  promoted  good  transduction
efficiency in ARPE19 cells (Figure 1) and is known to target
RPE in vivo following subretinal injection [32], we present
images  for  this  serotype  in  ARPE19  cells  (Figure  4A).
Similarly,  because  scAAV8  was  shown  to  efficiently
transduce 661W cells (Figure 1) and because this serotype is
known  to  target  photoreceptor  cells  in  vivo  following
subretinal injection [32], we present images for this serotype
in 661W cells (Figure 4D). In addition, images of scAAV2
and its respective sextuple mutant (shown to be the most
efficient of all capsid mutants tested via FACS analysis in
Figure 2) are shown in each cell line. While other serotypes
Figure  1.  Transduction  efficiency  of
unmodified scAAV vectors in ARPE19
and  661W  cells.  Cells  were  infected
with  scAAV1,  2,  5,  8,  and  9  at  a
multiplicity  of  infection  (MOI)  of
10,000. mCherry expression is shown in
arbitrary units calculated by multiplying
the percentage of positive cells by the
mean  fluorescence  intensity  in  each
sample.  Each  value  represents  the
average of three samples (eight pooled
wells of a 24-well plate/sample), based
on 10,000 counted cells.
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transduction efficiencies were too low to produce images with
discernable fluorescence in this assay. Consistent with the
results of our FACS analysis, fluorescent images show that
scAAV1  and  scAAV2  had  high  and  relatively  similar
transduction efficiencies in ARPE19 cells (Figure 4A, B). An
apparent increase in transduction efficiency was observed in
cells infected with the scAAV2 sextuple mutant; there were
more fluorescent cells and a stronger overall mCherry signal
within each cell (Figure 4C). The FACS analysis also showed
that even with an ~7 fold decrease in transduction efficiency
compared to scAAV2 (Figure 1), an infection with scAAV8
resulted in visible mCherry expression in 661W cells (Figure
4D,E). An increase in transduction efficiency was also seen
with the scAAV2 sextuple infection in 661W cells (Figure
4F). These results indicate that vectors ~7 fold less efficient
than  unmodified  scAAV2  may  still  be  visualized  via
fluorescent microscopy.
Transduction efficiency of scAAV1, scAAV8, and their single
Y-F  capsid  mutants:  Because  of  the  known  tropism  of
scAAV1 and scAAV8 for RPE and photoreceptors in vivo
[32],  respectively,  an  investigation  of  the  transduction
efficiencies of their single Y-F capsid mutants was performed.
Vectors infected in both cell lines included scAAV1, scAAV1
Y731F,  scAAV8,  scAAV8  Y733F,  and  scAAV8  Y447F.
Unmodified  scAAV1  had  relatively  high  transduction
efficiency  in  both  ARPE19  and  661W  cells  (Figure  1).
However,  the  respective  single  capsid  mutant  was  less
efficient in both cell lines (Figure 5A). The single capsid
mutant,  scAAV8  Y447F,  demonstrated  a  fourfold  and
threefold increase in transduction efficiency over scAAV8 in
ARPE19  and  661W  cells,  respectively.  However,  no
appreciable  increase  in  efficiency  was  noted  for
scAAV8Y733F over scAAV8 in either cell line.
ARPE19 cells can withstand lengthy post infection incubation
times: ARPE19 cells grow as a distinct monolayer capable of
living for months without being passaged if fed regularly with
serum-containing medium (data not shown). We sought to
determine whether ARPE19 cells would remain healthy for
up to 14 days after infection with AAV, the idea being that if
the cells remained healthy and continued to accumulate gene
product  as  a  function  of  time,  they  could  be  useful  in
developing  bioassays  requiring  maximal  viral-mediated
protein expression. In contrast to ARPE19 cells, we noted that
661W cells became overcrowded after a few days (data not
shown) and required regular passaging. For this reason, 661W
cells were not analyzed in this manner. Figure 6 demonstrates
the  long-term  viability  of  ARPE19  cells  infected  with
Figure  2.  Transduction  efficiency  of
unmodified  scAAV2  and  its  single/
multiple  Y-F  capsid  mutant  vectors.
Cells  were  infected  with  unmodified
scAAV2,  scAAV2  single  mutant
(Y444F),  double  mutant  (Y444F
+Y730F), triple mutant (Y444F+Y730F
+Y500F),  quadruple  mutant  (Y444F
+Y730F+Y500F+Y272F),  pentuple
mutant  (Y444F+Y730F+Y500F
+Y272F+Y704F), and sextuple mutant
(Y444F+Y730F+Y500F+Y272F
+Y704F+Y252F)  at  a  multiplicity  of
infection  (MOI)  of  10,000.  mCherry
expression is shown in arbitrary units
calculated  by  multiplying  the
percentage of positive cells by the mean
fluorescence intensity in each sample.
Each  value  represents  the  average  of
three samples (eight pooled wells of a
24-well plate/sample), based on 10,000
counted cells.
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1094scAAV2-smCBA-mCherry. An increase in gene product can
clearly be seen between 3 days and 7 days post infection
(Figure  6A,B).  Cells  remained  healthy  at  14  days  post
infection, but mCherry expression appeared only marginally
increased relative to that seen at 7 days post infection (Figure
6B,C). This suggests that maximal AAV-mediated transgene
expression was reached somewhere between 7 and 14 days
post infection.
Promoter analysis: We sought to evaluate a representative
selection  of  retina-specific  promoters  already  successfully
used  in  conjunction  with  AAV  in  proof-of-concept  gene
therapy  experiments.  scAAV2  vectors  expressing  green
fluorescent  protein  (GFP)  under  the  control  of  either
mCARpro  (cone-  targeting),  MOPS500  (rod-targeting),
VMD2  (RPE-targeting),  or  smCBA  (ubiquitous)  were
infected in both ARPE19 and 661W cells at an MOI of 10,000.
At  3  days  post  infection,  cells  were  immunostained  and
imaged. In ARPE19 cells, GFP expression was apparent in
infections  with  all  four  promoters  (Figure  7A-D).  The
ubiquitous smCBA promoter appeared to drive the highest
levels of GFP expression, followed by mCARpro, MOPS500,
and  VMD2.  GFP  expression  was  also  seen  in  all  four
infections in 661W cells (Figure 7E-H). Transduction was
most evident with the ubiquitous smCBA promoter followed
by mCARpro and MOPS500, which showed relatively equal
GFP expression. The VMD2 promoter appeared to be the least
effective in both cell lines (Figure 7C,G).
DISCUSSION
Here,  we  report  the  relative  transduction  efficiencies  of
several well characterized AAV serotypes and their respective
single/multiple tyrosine capsid mutants in two biologically
relevant ocular cell lines, ARPE19 (RPE) and 661W (cone
photoreceptor) cells. In addition, we examine the activity of
rod-specific,  cone-specific,  RPE-specific,  and  ubiquitous
promoters when delivered by scAAV2 to both lines. We chose
ARPE19  (human  origin)  and  661W  cells  (mouse  origin)
because: 1) they are derived from two retinal tissues, RPE and
cone photoreceptors, that are well established as viable targets
of  AAV-mediated  gene  therapy,  2)  both  cell  lines  are
increasingly used to model important physiologic processes
intrinsic to RPE and cone photoreceptors, and 3) both are easy
to  maintain  in  culture  and  therefore  adaptable  to  a  high
through-put application. Non-ocular cell lines, such as human
embryonic kidney (HEK293) and HeLa cells, are typically
used  to  assay  AAV  vectors  in  vitro  because  of  their
availability. However, with the exception of AAV2, many
serotypes  transduce  these  non-ocular  cell  lines  very
inefficiently. In addition, non-ocular HEK293 and HeLa cells
are often incapable of supporting photoreceptor-specific or
RPE-specific protein expression (data not shown). Here, we
report that scAAV serotypes 1, 2, 5, and 8, as well as scAAV1,
scAAV2,  and  scAAV8  capsid  mutants,  were  capable  of
transducing RPE and cone photoreceptor cell lines in vitro. In
addition, we show that photoreceptor-specific, RPE-specific,
and ubiquitous promoters are active in both cell lines. Our
results have implications for investigators seeking to optimize
AAV-based gene therapy vectors to treat retinal disease and/
or develop quick assays for qualifying clinical-grade vectors.
The  scAAV  serotypes,  1,  2,  and  5  transduce  both
ARPE19  and  661W  cells  relatively  well.  The  efficient
transduction of both cell lines by scAAV1 is not surprising
Figure 3. In vivo transduction pattern of AAV2 triple and sextuple Y-F capsid mutants. Green fluorescent protein (GFP) expression in retinal
sections of adult mice at one month following subretinal delivery of (A) AAV2 triple mutant (Y444F+Y730F+Y500F) or (B) sextuple mutant
(Y444F+Y730F+Y500F+Y272F+Y704F+Y252F) and (C) a comparison of the relative GFP fluorescence intensity in the retinal pigment
epithelium (RPE) layer of retinas treated with the triple and sextuple AAV2 vectors, respectively. Values indicate percent GFP intensity
relative to treatment with AAV2 triple mutant vector. All pictures were evaluated using Image J software. The data are shown as the mean
±SEM; n=3 for each group (p<0.0001). PR represents photoreceptor layer.
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1095given  the  reports  of  AAV1’s  preference  for  RPE  and
photoreceptors in vivo [32,33]. Likewise, scAAV8 transduces
661W cells more effectively than ARPE19s.This result is
consistent  with  reports  that  AAV8  primarily  transduces
photoreceptors and some RPE cells in vivo [32]. In fact, recent
reports show that AAV8 has been used to drive therapeutic
expression in and restore function to photoreceptors in several
models  of  inherited  retinal  degeneration,  including  Leber
congenital amaurosis (AIPL1 and RPGRIP forms) [34-36]
and X-linked juvenile retinoschisis [37]. Taken together, these
results indicate a degree of similarity between the patterns of
transduction expected of AAV1 and AAV8 in vitro and in
vivo. Likewise, we show that scAAV5 efficiently transduces
both cell lines, a result also consistent with AAV5′s preference
for  photoreceptors  and  RPE  in  vivo  [33].  In  comparison,
despite  its  ability  to  efficiently  transduce  both  RPE  and
photoreceptors  in  the  murine  retina  [38-40],  scAAV9
inefficiently transduces ARPE19 and 661W cells.
Mutations  of  surface-exposed  AAV  capsid  tyrosine
residues increase vector transduction kinetics and efficiency
relative to matched, unmodified vectors [41]. It is thought that
by  replacing  tyrosine  residues  with  phenylalanine,  these
vectors evade phosphorylation and subsequent ubiquitination,
thus preventing proteasome-mediated vector degradation and
facilitating intracellular trafficking of the vector genome to
the nucleus [41].
Accordingly, we show here that scAAV2 vectors with
capsids containing as few as one and as many as six Y-F
mutations  transduce  ARPE19  and  661W  cells  more
effectively than their unmodified counterpart, scAAV2. The
sextuple  mutant  (scAAV2  Y444F+Y730F+Y500F+Y272F
+Y704F+Y252F)  exhibited  the  highest  transduction
efficiency in both cell lines. However, it is interesting to note
that the relationship between the transduction efficiency of
scAAV2 vectors and the amount of Y-F mutations present on
their  capsids  is  not  linear.  While  still  more  efficient  that
standard scAAV2, we found that the transduction efficiency
of the quadruple mutant (scAAV2 Y444F+Y730F+Y500F
+Y272F) in both cell lines was reduced relative to vectors
containing  fewer  mutations.  The  addition  of  the  Y272F
Figure 4. scAAV-mediated mCherry expression in human retinal pigment epithelial (ARPE19) and 661W cone photoreceptor cells, at three
days post infection. The top row consists of representative images of mCherry expression in ARPE19 cells infected with (A) scAAV1, (B)
scAAV2, and (C) scAAV2 sextuple mutants at a multiplicity of infection (MOI) of 10,000. The bottom row consists of representative images
of mCherry expression in 661W cells infected with (D) scAAV8, (E) scAAV2, and (F) scAAV2 sextuple mutants at an MOI of 10,000. All
10× images were taken with identical exposure times (800 ms). The scale bar in A=200 µm.
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1096residue  (going  from  triple  to  quadruple  mutant)  had  a
substantial negative effect on transduction efficiency in the
661W cells. This pattern is consistent with what was observed
in a similar study, in which multiple scAAV2 Y-F mutants
were evaluated in HeLa cells and murine hepatocytes [42].
The mechanism underlying this Y272F-associated reduction
is unclear. It is possible that replacing a hydrophilic tyrosine
residue  at  position  272  of  the  capsid  protein  with  a
hydrophobic  phenylalanine  sufficiently  alters  surface
configuration and hinders binding, uptake, or retention of
vectors to/in its target cell. It would be interesting to evaluate
whether transduction efficiencies of the quadruple, pentuple,
and sextuple mutants would be further enhanced by removing
the  Y272F  mutation.  Our  observations  of  transduction
efficiencies in 661W cells are consistent with our previous
report of AAV2 multiple Y-F mutant-mediated transduction
in  mouse  retina  following  subretinal  injection  of  vectors
[31]. In vivo, the triple mutant was most efficiently expressed
in photoreceptors [31]. Here, we show the triple and sextuple
mutants were the most efficient at transducing 661W cells. In
both cases, there was a drop off in efficiency when moving
from  the  triple  to  the  quadruple  mutant.  However,  the
comparison is complicated by the fact that when delivered to
the subretinal space, the vector can also directly access RPE,
whereas in vitro, the vector is exposed to only one cell type.
Furthermore, our in vitro data indicates the sextuple mutant
transduces  ARPE19  cells  much  more  effectively  than  the
triple mutant (~3 fold better). We therefore investigated the
reproducibility of this result, in vivo, by examining whether
the  sextuple  mutant  would  show  improved  transduction
efficiency in RPE relative to the triple mutant when delivered
to the subretinal space. As predicted, the relative transduction
Figure  5.  Transduction  efficiency  of
unmodified  scAAV1,  scAAV8,  and
their  respective  single  Y-F  capsid
mutant vectors. Transduction efficiency
of scAAV1 and scAAV1 Y731F (A),
scAAV8,  scAAV8  Y733F,  and
scAAV8  Y447F  (B)  in  ARPE19  and
661W  cells  measured  by  mCherry-
mediated  and  fluorescence-activated
cell  sorting  (FACS)  analysis.  Data
represents infections at a multiplicity of
infection  (MOI)  of  10,000.  mCherry
expression is shown in arbitrary units
calculated  by  multiplying  the
percentage of positive cells by the mean
fluorescence intensity in each sample.
Each  value  represents  the  average  of
three samples (eight pooled wells of a
24-well plate/sample), based on 10,000
counted cells.
Figure 6. Human retinal pigment epithelial cell line (ARPE19) cells remain viable upon lengthy post infection incubation. mCherry expression
in ARPE19 cells infected with scAAV2-smCBA-mCherry at an MOI of 10,000 (A) 3 days, (B) 7 days, and (C) 14 days post infection. All
10× images were taken at identical exposure settings (800 ms). The scale bar in A=200 µm.
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1097efficiencies for the sextuple and triple mutants in vivo (RPE)
and  in  vitro  (ARPE19)  were  consistent.  The  increased
transduction  efficiencies  for  AAV2  Y-F  mutants  is  not  a
straightforward story, as they show enhanced transduction of
retinal layers distal to the injection site [31]. In particular,
when delivered to the vitreous, the AAV2 Y-F quadruple,
pentuple, sextuple, and septuple mutants transduced all retinal
layers,  including  photoreceptors  and  in  some  cases,  RPE
[31]. This potential for “penetration” cannot be modeled in
vitro, highlighting one limitation of cell-based assays.
Unlike the point mutations in scAAV2 capsids, which
generally  increased  transduction  efficiency  relative  to  the
unmodified  vector,  certain  single  point  mutations  on  the
scAAV1 and scAAV8 capsids examined here did not increase
the  transduction  efficiency  relative  to  their  unmodified
counterparts. In fact, scAAV1 Y731F was less efficient than
unmodified  scAAV1  in  both  ARPE19  and  661W  cells.
Likewise, the single Y733F mutation did not markedly alter
the transduction efficiency of scAAV8. It is worth noting that
731, 733, and 730 correspond to the equivalent capsid residues
of scAAV1, scAAV8, and scAAV2, respectively [43]. Is it
possible  that  inhibiting  phosphorylation  of  this  specific
residue  may  be  relatively  ineffective  at  increasing
transduction efficiencies of any AAV serotype? While we did
not test the corresponding single mutant in this study, scAAV2
Y730F has shown reduced efficiency in CD34+ stem cells
[44].  However,  scAAV2  Y730F  exhibited  improved
transduction relative to unmodified scAAV2 in HeLa cells
and murine hepatocytes in vitro, as well as murine retina and
hepatocytes in vivo [19,42]. We have shown that scAAV8
containing the corresponding single Y733F capsid mutation
mediates more rapid transgene expression than its unmodified
counterpart, scAAV8, in murine retina [19]. In addition, we
recently  demonstrated  that  the  AAV8  Y733F-vectored
transgene restored vision to a model of early-onset recessive
retinitis pigmentosa, the rd10 mouse model. This model is
refractory to long-term therapy with unmodified AAV8 [20].
As discussed, in light of the novel characteristics exhibited by
AAV2 multiple Y-F mutants, these results indicate that cell
lines in culture are not a perfect substitute for characterizing
in vivo vector behavior. There are additional factors at play
that affect transduction efficiency, which cell-based assays
will struggle to appropriately model. These include physical
barriers  to  vectors,  such  as  the  inner  limiting  membrane,
which restricts AAV-mediated transduction of the outer retina
following delivery of a vector to the vitreous cavity and which
varies in degree from species to species [45], immunological
barriers, either pre-existing immunity to AAV capsid protein
or  cell-mediated  immune  response  to  AAV  capsid  and/or
transgenes, which can block AAV-mediated gene expression,
again the degree to which varies widely among species [46].
The developmental state and/or condition of the target tissue,
Figure 7. Retina-specific promoters are capable of transducing both human retinal pigment epithelial cell line (ARPE19) and 661W cells.
Representative images of green fluorescent protein (GFP) expression in ARPE19 cells at 3 days post infection with AAV2 (A) sc-mCARpro-
GFP, (B) sc-MOPS500-eGFP, (C) sc-VMD2-GFP, and (D) sc-smCBA-GFP. Representative images of GFP expression in 661W cells at 3
days post infection with AAV2 (E) sc-mCARpro-GFP, (F) sc-MOPS500-eGFP, (G) sc-VMD2-GFP, and (H) sc-smCBA-GFP. All infections
were done at a multiplicity of infection (MOI) of 10,000. 10× images A-C and E-G were taken at an ET of 800 ms, whereas images D and
H were taken at an ET of 300 ms. The scale bar in A=200 µm.
Molecular Vision 2011; 17:1090-1102 <http://www.molvis.org/molvis/v17/a124> © 2011 Molecular Vision
1098the  observations  that  AAV  vectors  exhibit  different
transduction  patterns  when  delivered  to  developing  as
opposed to fully differentiated retina [47] and show enhanced
transduction  characteristics  in  degenerating  retina  [48],
highlight potential changes in cell surface receptors as well as
structural changes that ultimately effect AAV transduction.
However, as indicated by the example of our assay to correctly
make a prediction of in vivo transduction, in vitro models do
have utility. Given the immense number of capsid variants
likely to be available in the future, in vitro assays will be a
useful  first  step  in  characterizing  novel  variants  and  will
provide  important  clues  for  vector  design  strategies.  For
instance,  our  results  show  that  scAAV8  Y447F  exhibited
marked improvements in transduction efficiency relative to
unmodified scAAV8 in both cell lines. The same pattern was
seen  with  the  corresponding  single  mutant  [43],  scAAV2
Y444F.  This  result,  in  addition  to  the  observations  about
AAV8 Y733F in vivo, suggests that combining the Y444F and
Y733F mutations may have an additive effect. These and other
combinations of Y-F mutations are currently being made to
test this idea.
The  ARPE19  and  661W  cells  also  proved  useful  for
testing the activity of photoreceptor-specific, RPE-specific,
and ubiquitous promoters. This is an important finding given
the need to characterize vectors for retinal disease in cell-
based assays and that cell lines typically used for such in vitro
vector characterization (HEK293, HeLa) often do not support
expression of retinal-specific proteins. Here, we show that
cone-specific  (mCARpro),  rod-specific  (MOPS500),  RPE-
specific (VMD2), and ubiquitous (smCBA) promoters were
active in both cell lines. All promoters qualitatively appeared
to  be  more  active  in  ARPE19  cells  than  in  661Ws.
Nevertheless,  GFP  expression  from  scAAV2  vectors
containing each promoter could be visualized in both lines.
As expected, the strong smCBA promoter drove the most
robust reporter expression, as it does in vivo. The recently
characterized  ‘mCARpro’  promoter  also  drove  robust
expression in ARPE19 cells. This result is similar to what we
have seen and others have reported for mouse retinas [31,
49]. Interestingly, we found the VMD2 promoter, which has
demonstrated RPE-specificity in vivo [50], reduced activity
in  the  ARPE19  cells  relative  to  the  two  photoreceptor
targeting promoters. Overall, the pattern of expression in the
661W cells was more consistent with what would be predicted
based on in vivo characteristics of the promoters, with the
cone-targeting  mCARpro  performing  better  than  the  rod-
targeting MOPS500s and better still than the VMD2 promoter.
In  addition  to  their  utility  for  screening  a  variety  of
unmodified  and  modified  scAAV  serotypes  and  various
retina-specific and ubiquitous promoters, we also show that
ARPE19 cells maintain viability upon long incubation times.
Because many cells, including 661Ws, grow without contact
inhibition in culture until they become overcrowded and die,
assays for vector-mediated transgene expression must be done
within a few days of infection. On the other hand, ARPE19
cells grow in culture until they successfully form a healthy
monolayer  that  persists  for  months.  Here,  we  show  that
ARPE19 cells can be transduced with an AAV vector and
assayed as late as two weeks post infection (the latest time
point evaluated), a length of time not afforded by traditional
cell lines. This may be critical for investigators seeking to
evaluate expression of AAV-vectored proteins that require
longer  incubation  times  to  reach  detectable  levels  of
expression. Additionally, those interested in evaluating the
long-term effects of AAV-mediated transgene expression or
simply evaluating the long-term effects of AAV transduction
alone on cellular physiology may consider using ARPE19
cells.
Using  FACS  analysis,  we  have  developed  a  high-
throughput  assay  for  quantifying  the  relative  transduction
efficiencies of a variety of self-complementary AAV vectors
in two ocular cell lines, RPE-derived, ARPE19, and cone
photoreceptor-derived  661W.  Both  lines  were  used  to
compare the efficiency of scAAV vectors that have either
unmodified  capsids  or  capsids  containing  single/multiple
tyrosine-phenylalanine (Y-F) mutations. Quantification with
FACS was supplemented with qualitative analysis of vector
performance in each cell line via imaging of reporter protein
(mCherry)  expression.  With  limited  exceptions,  the
transduction profiles of vectors transduced into ARPE19 and
661W cells are consistent with reports of their behavior in
vivo. In addition, we have shown that both ocular cell lines
support  the  activity  of  rod-specific,  cone-specific,  RPE-
specific, and ubiquitous promoters, albeit to different degrees.
The ARPE19 cells remained viable for at least two weeks post
infection, a factor that makes this cell line useful for long-term
in vitro assays. The recent success of several ongoing clinical
trials  for  RPE65-Leber  congenital  amaurosis-2  as  well  as
proof-of-concept studies involving mice, dogs, and monkeys
have established that AAV-mediated gene replacement is a
feasible  strategy  for  treating  a  wide  variety  of  RPE  and
photoreceptor-specific disorders. Our results suggest that this
rapid cell-based assay using two biologically relevant ocular
cell  lines  will  prove  a  useful  adjunct  in  screening  and/or
optimizing vector constructs and can be used in conjunction
with  small  molecules/drugs  aimed  at  increasing  AAV
transduction efficiency.
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